Seeking Alpha

BioShockers'  Instablog

BioShockers
Send Message
BioShockers.com is a recently created biotech investing website that is focused on finding high-potential, low-price, and legitimate biotech/pharma companies. The great majority of stocks we will do write-ups on will be on one of three exchanges, NASDAQ, AMEX, or NYSE. Occasionally, we will... More
  • Sunesis - Voreloxin & ASCO 0 comments
    May 10, 2010 11:10 AM | about stocks: SNSS

    Sunesis is a biopharmaceutical company focused on the development of their lead anti-cancer drug Voreloxin. Voreloxin is being tested for the treatment of AML (Acute Myeloid Leukemia) and Platinum-Resistant Ovarian Cancer.

    In December, 2009, Sunesis presented positive results in two P2 trials of Voreloxin in AML. The results brought much-needed attention to the stock, and brought it as high as $2.43. Since then, the stock has pulled back to the $0.90 range.

    Also, due to the positive P2 results in AML, Sunesis announced that they will be moving Voreloxin into a pivotal P3 trial, which they expect to initiate in the second half of 2010.

    On June 7, at the annual ASCO (American Society of Clinical Oncology) meeting, Sunesis will present trial results from P2 trials in AML and Ovarian Cancer -- they have an oral presentation in ovarian cancer (a big deal for a small company like Sunesis).

    Sunesis represents a unique investment opportunity, they have just under 60M shares outstanding, a potential blockbuster cancer drug (Voreloxin), possibly some great ovarian cancer data, and the fairly-likely possibility of a runup in anticipation of ASCO.

    Please read our disclaimer in our bio before investing in any stock that we write an article on.

    BioShockers.com is a recently created investment website, with a fully functional FDA Calendar, Blog, and Research on biotech stocks.



    Disclosure: Long SNSS
    Themes: Biotech, Pharma Stocks: SNSS
Back To BioShockers' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.